COMMONS

The Future of AstraZeneca

The Business, Innovation and Skills Committee took evidence on Pfizer's proposed takeover of AstraZeneca on Tuesday 13 May 2014.

News

What's on

Date Business

No business announced

Publications

  • Close

    Glossary

    • Reports and associated evidence – Reports of Committee inquires. This category may also include Special Reports where they are used by a Committee to bring matters relating to conduct of its business to the notice of the House.
    • Responses to Reports - Responses may be published as a Special Report, or as a Command Paper. They may also be appended to a Report should the Committee have substantial comments on the Response, in which case they can be found listed under Reports. 
    • Other oral and written evidence - Evidence taken by the Committee that has yet to or did not result in the publication of a Report. This includes transcripts of recent meetings.
    • Estimate Memoranda - An Estimate memorandum is an explanatory note that accompanies a government department’s estimate (a means by which a department seeks authority from Parliament for its spending plans).
    • Correspondence - Correspondence sent from or received by the Committee or its Chair.
  • 13 May 2014 - The future of AstraZeneca - oral evidence | PDF version (PDF514 KB) HC 1286 | Published 14 May 2014

    Evidence given by Tony Burke, Assistant General Secretary, Unite, Allan Black, National Officer, GMB (at 09:30); Ian Read, Chairman and Chief Executive, Pfizer Inc., Frank D'Amelio, Executive Vice President, Business Operations and Chief Financial Officer, Pfizer Inc., Jonathan Emms, UK Managing Director, Pfizer Inc. (at 10:00); Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca plc, Mene Pangalos, Executive Vice President, Innovative Medicines & Early Development, AstraZeneca plc, Dr Jane Osbourn, Vice President, R&D Medlmmune Cambridge (at 11:15); Rt Hon. Dr Vince Cable MP, Secretary of State for Business, Innovation and Skills (at 13:00).